FY2025 EPS Estimates for DNLI Decreased by Cantor Fitzgerald

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued on Thursday, April 10th. Cantor Fitzgerald analyst J. Schimmer now anticipates that the company will earn ($3.04) per share for the year, down from their prior forecast of ($3.00). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share.

DNLI has been the topic of several other research reports. Baird R W upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Tuesday, January 7th. Robert W. Baird started coverage on shares of Denali Therapeutics in a report on Tuesday, January 7th. They issued an "outperform" rating and a $31.00 target price for the company. HC Wainwright upped their price objective on shares of Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a research report on Friday, February 28th. B. Riley reissued a "buy" rating and issued a $35.00 price objective (down previously from $38.00) on shares of Denali Therapeutics in a research note on Wednesday, March 5th. Finally, Bank of America decreased their target price on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $37.57.

Denali Therapeutics Stock Performance

Shares of NASDAQ DNLI traded up $0.19 during trading hours on Monday, hitting $12.74. 979,179 shares of the stock were exchanged, compared to its average volume of 1,081,317. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $33.33. The company has a market cap of $1.85 billion, a PE ratio of -4.62 and a beta of 1.58. The company's fifty day simple moving average is $15.78 and its two-hundred day simple moving average is $21.43.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.08.

Institutional Investors Weigh In On Denali Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC grew its position in shares of Denali Therapeutics by 589.9% during the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares during the period. GF Fund Management CO. LTD. bought a new stake in Denali Therapeutics in the fourth quarter valued at $62,000. Point72 Hong Kong Ltd acquired a new position in shares of Denali Therapeutics during the fourth quarter valued at about $65,000. PNC Financial Services Group Inc. boosted its position in shares of Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after purchasing an additional 885 shares in the last quarter. Finally, KBC Group NV increased its position in Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after buying an additional 2,731 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.